A new study has found undetectable serum levels of HBV DNA at week 24 of treatment to be the strongest predictor of optimal outcomes for patients with chronic HBV infection. Although this finding is not surprising, it has important implications for those patients on antiviral therapy who do not achieve a favorable response.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65–73 (2006).
Iloeje, U. H. et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130, 678–686 (2006).
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J. Hepatol. 50, 227–242 (2009).
Liaw, Y. F. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521–1531 (2004).
Zeuzem, S. et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 51, 11–20 (2009).
Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49, 1503–1514 (2009).
Snow-Lampart, A. et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 MG QD [abstract 977]. Hepatology 48 (Suppl. 1), 745A (2008).
Bonino, F. et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56, 699–705 (2007).
Fried, M. W. et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47, 428–434 (2008).
Brunetto, M. R. et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49, 1141–1150 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Nguyen, T., Locarnini, S. Monitoring drug therapy for hepatitis B—a global challenge?. Nat Rev Gastroenterol Hepatol 6, 565–567 (2009). https://doi.org/10.1038/nrgastro.2009.160
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.160
This article is cited by
-
Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs
Frontiers of Medicine (2017)